Introducing
A/Prof Tomas Kalincik
Hello, I’m Tomas, Head of the Clinical Outcomes Research (CORe) Unit.
a little bit about me
I am the Head of the CORe Unit at the University of Melbourne, as well as the Head of the Multiple Sclerosis and Neuroimmunology Service at the Royal Melbourne Hospital.
Together with the CORe team, I specialise in analytics of observational data in neurology. I am an active participant in the global MSBase collaboration, undertaking a role in the MSBase Scientific Leadership Group.
My research interests revolve around disease outcomes in multiple sclerosis and Neuromyelitis Optica. These comprise comparative treatment effectiveness, management of treatment failure, individual treatment response, personalised therapy, prognostics, epidemiology and utility of volumetric MRI.
Publications
- Treatment response score to glatiramer acetate or interferon beta-1a.
- Correction to: Serum microRNA is a biomarker for post-operative monitoring in glioma.
- Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.
- Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
- Comparative effectiveness of rituximab in multiple sclerosis.
- Association of Pregnancy With the Onset of Clinically Isolated Syndrome.
- Serum microRNA is a biomarker for post-operative monitoring in glioma.
- Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
- COVID-19 in people with multiple sclerosis: A global data sharing initiative.
- Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
- Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
- Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
- The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis.
- Early clinical markers of aggressive multiple sclerosis.
- The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities, and neuropsychiatric symptoms.
- Monitoring of radiologic disease activity by serum neurofilaments in MS.
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
- Correction to: Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial.
- Presentation and outcome of patients with intracranial tuberculoma in a high HIV prevalence setting.
- Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
- Psychometric properties of the Hospital Anxiety and Depression Scale in an inpatient video-monitoring epilepsy cohort.
- Distinct psychopathology profiles in patients with epileptic seizures compared to non-epileptic psychogenic seizures.
- Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
- Abbreviated assessment of psychopathology in patients with suspected seizure disorders.
- Personality profiles differ between patients with epileptic seizures and patients with psychogenic non-epileptic seizures.
- Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.
- PACS Integration of Semiautomated Imaging Software Improves Day-to-Day MS Disease Activity Detection.
- Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
- Risk of secondary progressive multiple sclerosis: A longitudinal study.
- Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.
- The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis.
- The MSBase registry: Informing clinical practice.
- Effectiveness of oral multiple sclerosis therapies in clinical context.
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
- Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
- Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.
- Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
- Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
- Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
- Where there is inflammation, treatment may reduce disability progression - Yes.
- Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
- Defining secondary progressive multiple sclerosis.
- Observational data: Understanding the real MS world.
- Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
- Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
- Data quality evaluation for observational multiple sclerosis registries.
- Olfactory ensheathing cells but not fibroblasts reduce the duration of autonomic dysreflexia in spinal cord injured rats.
- Treatment decisions in multiple sclerosis - insights from real-world observational studies.
- Impairment of Smooth Pursuit as a Marker of Early Multiple Sclerosis.